Variants in FAM13A are associated with chronic obstructive pulmonary disease (original) (raw)

References

  1. Rabe, K.F. et al. Am. J. Respir. Crit. Care Med. 176, 532–555 (2007).
    Article Google Scholar
  2. Silverman, E.K. Proc. Am. Thorac. Soc. 3, 405–408 (2006).
    Article CAS Google Scholar
  3. Pillai, S.G. et al. PLoS Genet. 5, e1000421 (2009).
    Article Google Scholar
  4. Fishman, A. et al. N. Engl. J. Med. 348, 2059–2073 (2003).
    Article Google Scholar
  5. Bell, B. et al. Aging Hum. Dev. 3, 5–17 (1972).
    Article Google Scholar
  6. Wilk, J.B. et al. PLoS Genet. 5, e1000429 (2009).
    Article Google Scholar
  7. Vestbo, J. et al. Eur. Respir. J. 31, 869–873 (2008).
    Article CAS Google Scholar
  8. Cohen, M. et al. Genomics 84, 374–383 (2004).
    Article CAS Google Scholar
  9. Chi, J.T. et al. PLoS Med. 3, e47 (2006).
    Article Google Scholar
  10. Wade, K.C. et al. Am. J. Respir. Cell Mol. Biol. 34, 727–737 (2006).
    Article CAS Google Scholar
  11. Wright, J.M. et al. Am. J. Respir. Cell Mol. Biol. 35, 327–336 (2006).
    Article CAS Google Scholar
  12. Hancock, D.B. et al. Nat. Genet. 42, 45–52 (2010).
    Article CAS Google Scholar
  13. Repapi, E. et al. Nat. Genet. 42, 36–44 (2010).
    Article CAS Google Scholar
  14. Wellcome Trust Case Control Consortium. Nature 447, 661–678 (2007).
  15. Thorgeirsson, T.E. et al. Nature 452, 638–642 (2008).
    Article CAS Google Scholar

Download references

Acknowledgements

This work was supported by US National Institutes of Health (NIH) grants R01 HL075478, R01 HL084323, P01 HL083069, U01 HL089856 (E.K.S.), K12HL089990 (M.H.C) and U01 HL089897 (J.D.C.). The National Emphysema Treatment Trial was supported by the National Heart, Lung, and Blood Institute, the Centers for Medicare and Medicaid Services and the Agency for Healthcare Research and Quality. The Normative Aging Study is supported by the Cooperative Studies Program/ERIC of the US Department of Veterans Affairs and is a component of the Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC). The Norway cohort, the ECLIPSE study (Clinicaltrials.gov identifier NCT00292552; GSK Code SCO104960) and the ICGN study are funded by GlaxoSmithKline. Further acknowledgments are given in the Supplementary Note.

Author information

Author notes

  1. Sreekumar G Pillai
    Present address: Current address: Hoffman La Roche, Nutley, New Jersey, USA.,

Authors and Affiliations

  1. Channing Laboratory, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Michael H Cho, Nadia Boutaoui, Barbara J Klanderman, Jody S Sylvia, John P Ziniti, Craig P Hersh, Dawn L DeMeo, Gary M Hunninghake, Augusto A Litonjua & Edwin K Silverman
  2. Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA
    Michael H Cho, Craig P Hersh, Dawn L DeMeo, Gary M Hunninghake, Augusto A Litonjua & Edwin K Silverman
  3. Veterans Administration Boston Healthcare System, Boston, Massachusetts, USA
    David Sparrow
  4. School of Public Health, Boston University, Boston, Massachusetts, USA
    David Sparrow
  5. School of Medicine, Boston University, Boston, Massachusetts, USA
    David Sparrow
  6. Harvard School of Public Health, Harvard University, Boston, Massachusetts, USA
    Christoph Lange & Sungho Won
  7. National Jewish Medical and Research Center, Denver, Colorado, USA
    James R Murphy, Elizabeth A Regan, Barry J Make & James D Crapo
  8. Johns Hopkins School of Public Health, Baltimore, Maryland, USA
    Terri H Beaty
  9. Department of Epidemiology, Colorado School of Public Health, University of Colorado Denver, Aurora, Colorado, USA
    John E Hokanson
  10. GlaxoSmithKline Research and Development, King of Prussia, Pennsylvania
    Xiangyang Kong & Ruth Tal-Singer
  11. GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina, USA
    Wayne H Anderson & Sreekumar G Pillai
  12. Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
    David A Lomas
  13. Haukeland University Hospital and Institute of Medicine, University of Bergen, Bergen, Norway
    Per Bakke & Amund Gulsvik

Authors

  1. Michael H Cho
  2. Nadia Boutaoui
  3. Barbara J Klanderman
  4. Jody S Sylvia
  5. John P Ziniti
  6. Craig P Hersh
  7. Dawn L DeMeo
  8. Gary M Hunninghake
  9. Augusto A Litonjua
  10. David Sparrow
  11. Christoph Lange
  12. Sungho Won
  13. James R Murphy
  14. Terri H Beaty
  15. Elizabeth A Regan
  16. Barry J Make
  17. John E Hokanson
  18. James D Crapo
  19. Xiangyang Kong
  20. Wayne H Anderson
  21. Ruth Tal-Singer
  22. David A Lomas
  23. Per Bakke
  24. Amund Gulsvik
  25. Sreekumar G Pillai
  26. Edwin K Silverman

Contributions

Study design: E.K.S., M.H.C., A.A.L., D.S., S.G.P., X.K., W.H.A., R.T.-S., D.A.L., P.B., A.G., J.R.M., T.H.B., E.A.R., B.J.M., J.E.H., J.D.C., C.P.H. and D.L.D. Sample collection and phenotyping: A.A.L., D.S., S.G.P., X.K., W.H.A., R.T.-S., D.A.L., P.B., A.G., E.A.R., B.J.M., J.D.C., E.K.S. Genotyping: N.B., B.J.K., M.H.C., S.G.P., X.K. Informatics: M.H.C., J.S.S., J.P.Z., B.J.K., N.B. Statistical analysis: M.H.C., C.L., S.W., E.K.S. Manuscript writing: M.H.C., G.M.H., E.K.S. All authors reviewed and approved the manuscript.

Corresponding author

Correspondence toEdwin K Silverman.

Ethics declarations

Competing interests

E.K.S. has received grant support and consulting and speaker's fees from GlaxoSmithKline, consulting and speaker's fees from Astra-Zeneca and speaker's fees from Bayer and Wyeth. D.A.L. has received grant support, lecture fees and consultancy fees from GlaxoSmithKline. S.G.P, X.Q.K., W.H.A. and R.M.T. are employees of GlaxoSmithKline.

Supplementary information

Rights and permissions

About this article

Cite this article

Cho, M., Boutaoui, N., Klanderman, B. et al. Variants in FAM13A are associated with chronic obstructive pulmonary disease.Nat Genet 42, 200–202 (2010). https://doi.org/10.1038/ng.535

Download citation